Medifast financials
$11.61−0.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $385.8M | $602.5M | $1.07B | $1.60B | $1.53B | $934.8M | $713.7M | $501.0M | $301.6M | $274.5M |
| Gross profit | $275.2M | $444.6M | $775.9M | $1.14B | $1.13B | $697.8M | $536.9M | $379.9M | $227.8M | $205.7M |
| Gross margin | 71.3% | 73.8% | 72.4% | 71.3% | 73.9% | 74.6% | 75.2% | 75.8% | 75.5% | 74.9% |
| Operating income | -$14.2M | $2.9M | $126.4M | $184.8M | $216.2M | $134.2M | $91.0M | $69.1M | $39.6M | $26.9M |
| Net income | -$18.7M | $2.1M | $99.4M | $143.6M | $164.0M | $102.9M | $77.9M | $55.8M | $27.7M | $17.8M |
| Net margin | −4.8% | 0.3% | 9.3% | 9.0% | 10.7% | 11.0% | 10.9% | 11.1% | 9.2% | 6.5% |
| Diluted EPS | $-1.70 | $0.19 | $9.10 | $12.73 | $13.89 | $8.68 | $6.43 | $4.62 | $2.29 | $1.49 |
| EBITDA | $29.0K | $15.6M | $139.5M | $195.8M | $223.1M | $138.8M | $96.1M | $74.1M | $44.5M | $32.7M |
| Operating cash flow | $6.9M | $24.5M | $147.7M | $194.6M | $94.5M | $145.2M | $84.3M | $60.8M | $43.2M | $25.4M |
| Free cash flow | $1.2M | $17.0M | $141.2M | $177.9M | $60.3M | $139.3M | $74.2M | $55.9M | $40.0M | $22.5M |
| Diluted shares | 11.0M | 11.0M | 10.9M | 11.3M | 11.8M | 11.9M | 12.1M | 12.1M | 12.1M | 11.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $89.3M | $90.9M | $94.4M | $87.7M | $104.2M | $163.7M |
| Short-term investments | $78.0M | $71.4M | $55.6M | $0.00 | $5.4M | $10.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $248.0M | $284.2M | $309.9M | $316.2M | $398.3M | $276.1M |
| Total liabilities | $49.1M | $74.1M | $108.4M | $161.2M | $195.9M | $118.8M |
| Shareholders' equity | $198.9M | $210.1M | $201.5M | $155.0M | $202.5M | $157.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology